The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account